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CLINICAL AND LABORATORY FEATURES OF PATIENTS WITH COMORBID 




The relevance of the study is due to the increased prevalence of the phenotype of bronchial asthma with obesity and its 
more severe course. The purpose of the study was to investigate the effect of excess body weight on the parameters of the clinical 
and laboratory condition of patients with bronchial asthma. 132 patients with bronchial asthma (76 women and 56 men), aged 35–
60 years, 30 patients with normal weight and 102 patients with a body mass index of 25.0 kg/m2 and more were examined. It was 
found that overweight patients with bronchial asthma have a longer duration of the disease (by 28.6 %) and corticosteroids (by 
27.0 %), higher cardiovascular risk associated with increased diastolic blood pressure (by 5.3 %), decreased high-density 
lipoprotein (by 65.7 %), an increase in low-density lipoprotein (by 13.2 %) and glucose levels (by 5.1 %), an increase in 
interleukin-6 (by 31.8 %). Overweight correlations with age, spirometry, and symptom control were found in patients with asthma. 
Key words: bronchial asthma, obesity, symptom control, disease course, cardiovascular risk 
 
М.М. Кочуєва, В.Г. Псарьова, Г.А. Тимченко, О.С. Коміссарова, А.В. Марченко,  
М.Є. Тимченко, Ю.О. Заікіна 
КЛІНІКО-ЛАБОРАТОРНІ ОСОБЛИВОСТІ ХВОРИХ  
З КОМОРБІДНІСТЮ БРОНХІАЛЬНОЇ АСТМИ ТА ОЖИРІННЯ 
 
Актуальність роботи обумовлена збільшенням поширеності фенотипу бронхіальної астми з ожирінням та його 
більш важким перебігом. Мета роботи – дослідити вплив надлишкової маси тіла на параметри клініко-лабораторного 
стану хворих на бронхіальну астму. Обстежено 132 хворих на бронхіальну астму (76 жінок та 56 чоловіків), віком 35–60 
років, 30 хворих з нормальною вагою та 102 хворих з індексом маси тіла від 25,0 кг/м2 і більше. Встановлено, що хворі 
на бронхіальну астму з надлишковою вагою мають більшу тривалість захворювання (на 28,6 %) та прийому 
кортикостероїдів (на 27,0 %), вищий серцево-судинний ризик, асоційований з підвищенням рівня діастолічного 
артеріального тиску (на 5,3 %), зниженням ліпопротеїдів високої щільності (на 65,7 %), підвищенням ліпопротеїдів 
низької щільності (на 13,2 %) та рівня глюкози (на 5,1 %), збільшенням інтерлейкіну-6 (на 31,8 %). Виявлені кореляції 
надмірної ваги у хворих на бронхіальну астму з віком, показниками спірометрії та рівнем контролю симптомів. 
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Bronchial asthma (BA) is a chronic inflammatory disease of the respiratory tract, characterized by 
many phenotypes [4]. Large population studies show an increase in the prevalence of BA among obese 
patients regardless of their age [6, 10]. Obesity has become a global epidemic, the prevalence of which has 
tripled in the last two decades [2]. Currently, the combination of BA and obesity is considered as a 
phenotype with its own clinical, biological and functional features. 
The group of patients with BA on the background of obesity is not homogeneous. To date, two 
main phenotypes of the combination of asthma and obesity have been identified [1]:  
with an early onset of the disease, this is a variant of allergic asthma with an increase in type 2 T-helpers 
which is complicated by inflammatory processes in excess adipose tissue, and has a severe course of BA; 
with a late onset, this is a variant of non-atopic asthma, most often found in women, accompanied 
by less pronounced inflammation of the respiratory tract than the first variant, but characterized by 
significant General metabolic changes and manifestations of oxidative stress of the respiratory tract, the 
development of this type is also affected by chronic compression of the lungs caused by obesity of the chest 
walls [9, 12]. 
According to the latest report of the Global Initiative for Asthma (GINA) in 2021, the obesity 
asthma phenotype is associated with a severe course and difficulties in achieving control of symptoms with 
standard baseline therapy [4]. The comorbid course of asthma and obesity is accompanied by a greater 
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number of symptoms, worse indicators of external respiratory function (RF) and quality of life, insufficient 
response to the control therapy of asthma compared with the isolated form of asthma [10, 11], which in 
turn leads to an increase in the number of exacerbations of asthma and seeking medical help [9, 12]. 
Therefore, there is an urgent need for new treatment strategies for these patients. Weight loss is 
undoubtedly the leading approach, as numerous studies have shown that significant weight loss improves 
the symptoms of BA, RF, reduces the number of exacerbations and the risk of comorbidities such as 
cardiovascular disease and diabetes [11]. Bariatric treatment techniques are the most effective method of 
achieving weight loss [3], but bariatric surgery may be contraindicated in many overweight and obese 
patients with BA, therefore, non-surgical approaches are crucial for the treatment of asthma populations 
with obesity.  
Despite the large number of studies on the combination of asthma and obesity, the mechanisms of 
pathogenesis, clinical and laboratory features, the impact on quality of life and the response to control 
therapy of comorbid course of these pathologies still remain unclear, and no specific recommendations 
have been developed for the comprehensive treatment of asthma with obesity, taking into account the needs 
of diet therapy and physical rehabilitation of this group of patients. 
The purpose of the study was to investigate the effect of excess body weight on the parameters of 
the clinical and laboratory condition of patients with bronchial asthma. 
Materials and methods. The study performed during 2018-2020 on the basis of the Department 
of Pulmonology of the Municipal Non-Commercial Enterprise “City Clinical Hospital No. 13” of the 
Kharkiv City Council (Kharkiv, Ukraine). The study included 132 patients with persistent BA of moderate 
severity. The diagnosis was established according to GINA recommendations [4]. 
 
According to the Body Mass Index (BMI 
= body weight, kg/height, m2), all patients 
were divided into two groups. The first group 
consisted of patients with a BMI of 18.5 to 24.9 
kg/m2, which is normal weight, and the second 
group consisted of overweight patients (BMI 
from 25.0 kg/m2 to 29.9 kg/m2) and obese 
patients (BMI from 30.0 kg/m2 and more). 
Among the patients, there were 76 
women and 56 men, the groups were similar in 
gender composition (p>0.05) (fig. 1). Fig. 1. Distribution in study groups by gender 
The study involved patients aged 35–60 years, the mean age was 52.64±8.24 years, in the group 
with a normal BMI – 53.20±9.16 years, in the overweight group – 52.52±7.99 years (p>0.05) (fig. 2). 
 
Exclusion criteria were: diabetes 
mellitus, chronic infectious, systemic, 
oncological and psychiatric diseases and 
chronic heart failure with left ventricular 
ejection fraction less than 55 %, history of 
myocardial infarction, stroke and signs of 
coronary heart disease. 
The study was conducted in accordance 
with the Declaration of Helsinki adopted by the 
General Assembly of the World Medical 
Association, the European Union Convention 
on Human Rights and Biomedicine, Good 
Clinical Practice (GCP), relevant provisions of 
the World Health Organization (WHO) and 
Ukrainian law. All patients signed informed 
consent to participate in the clinical trial. Fig. 2. Age composition of the studied groups 
All patients underwent an examination, which included: general clinical examination – history 
taking and objective examination with anthropometric assessment of body weight, height, and 
calculation of body mass index (BMI), measurement of blood pressure (BP); a questionnaire using the 
Asthma Control Questionnaire-5 (ACQ-5) to determine the level of BA control; spirography using a 
computer system “SPIROCOM” (produced by the Research Institute “HAI-Medica”, Kharkiv); 
laboratory tests – clinical blood test with a detailed leukocyte formula, determination of blood glucose 
levels, analysis of lipid profile indicators (low-density lipoproteins (LDL), high-density lipoproteins 
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(HDL), total cholesterol), analysis of the content of immunoglobulin E (IgE), the content of interleukin-
4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8) was determined by the method of solid-phase enzyme-
linked immunosorbent assay. 
All patients received standard baseline therapy with inhaled corticosteroids (ICS) and β2-agonists 
of prolonged action according to the severity of the disease according to the recommendations of GINA 
[2]. The groups were comparable in age and asthma severity. 
The obtained data were processed using the Statistica software. Quantitative data are presented as mean 
values (M) and standard deviations (SD). The critical value of the level of statistical significance in testing the 
null hypotheses was assumed to be equal to 0.05. To compare the central parameters of the groups, we used 
parametric and nonparametric methods: Student's t-test, Wilcoxon   and   Mann-Whitney   tests.  The Mann-
Whitney U-test was used to pairwise compare the groups, and the Spearman correlation coefficient was 
used to determine the relationship between the traits. 
Results of the study and their discussion. Obesity in patients with BA is recognized as an 
important concomitant pathology that forms a unique phenotype and endotype. This comorbid condition 
reflects the close relationship between metabolic and inflammatory dysregulation. This study is devoted to 
the study of clinical and laboratory features of the course of BA on the background of different 
trophological status of patients. 
According to the criterion of division into groups – BMI, the first group included patients with BA 
with normal weight (22.33±0.37), and the second – with overweight (30.76±4.34) (p<0.05). Patients with 
BA with overweight compared to the group with normal body weight had a significantly longer duration 
of the disease and the use of ICS by 28.6 % and 27.0 %, respectively (p<0.05) (Table 1), which in turn may 
indicate an earlier onset of BA and the need for ICS in this group of patients.  
Table 1 
Clinical and laboratory characteristics of the examined groups of patients (m±SD) 
Index 
All patients with BA 
BA patients with 
normal BMI 
BA patients with 
excessive BMI 
p 
n=132 n=30 n=102 p 
BA duration, years 16.28±9.87 12.43±8.61 17.41±9.97 0.0114 
ICS duration, years 9.30±6.74 7.23±6.13 9.90±6.82 0.0493 
ACQ-5, points 1.21±0.25 1.20±0.25 1.22±0.25 0.7446 
FEV1, % prop. 67.11±5.96 68.20±6.08 66.79±5.92 0.2599 
Systolic BP, mm Hg 133.71±14.71 129.33±18.18 135.00±13.35 0.0867 
Diastolic BP, mm Hg 86.44±10.22 82.83±11.35 87.50±9.67 0.0328 
IL-4, pg/ml 133.71±14.71 59.47±3.78 66.20±22.30 0.1645 
IL-6, pg/ml 99.24±44.65 73.00±7.03 106.96±43.53 0.0003 
IL-8, pg/ml 6.01±3.81 5.34±0.36 6.21±4.18 0.8855 
Glucose, mmol/L 5.07±1.29 4.87±1.82 5.13±1.09 0.0366 
LDL, mmol/L 3.16±0.70 2.83±0.40 3.26±0.74 0.0058 
HDL, mmol/L 1.21±0.83 1.74±0.86 1.05±0.76 0.0007 
Total cholesterol, mol/L 5.91±1.41 5.78±1.81 5.95±1.28 0.0939 
IgE, IU/mL 804.97±1103.35 522.68±922.89 885.24±1140.80 0.2569 
eosinophils, % 3.37±3.87 3.20±3.18 3.42±4.06 0.7363 
 
There was a significant difference in the level of diastolic blood pressure: BA patients with 
overweight had a 5.3 % higher diastolic blood pressure compared with patients with asthma with normal 
body weight (p<0.05). In the comparative assessment of groups of BA patients with normal weight and 
overweight, significant differences in other clinical and anamnestic parameters, RF and level of control 
were not detected (p>0.05). 
Comparative analysis of systemic inflammation in the studied groups of patients showed a higher 
level of IL-6 by 31.8 % in the overweight group of BA patients compared with the group with normal BMI 
(p<0.05), although the levels of IL-4 and IL-8 did not have significant differences in these groups. 
In the group of overweight patients with BA compared to the group with normal weight, glucose 
levels were significantly higher (by 5.1 %), although the average glucose levels in both groups were within 
normal limits (5.13±1.09 and 4.87±1.82, respectively). 
Evaluation of lipid metabolism revealed a 13.2 % higher LDL level and a 65.7 % lower HDL level 
in overweight patients with BA compared to normal-weight patients with BA (p<0.05), which may indicate 
an increased cardiovascular risk in this group of patients. 
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Indicators associated with the allergic profile of BA (IgE and eosinophils) did not have significant 
differences in the groups of normal weight and overweight patients with asthma.  
To establish the relationship and determine the pathogenetic role of excess body weight (increased 
BMI) and the studied indicators, a correlation analysis was performed to determine the Spearman 
correlation coefficient (table 2).  
Table 2 
Correlations of BMI in the group of BA patients with elevated BMI 
Indices r p-value 
Patient's age, years 0.299 0.002 
Disease duration, years 0.098 0.328 
FEV1 before treatment, % -0.206 0.038 
ACQ-5, points 0.274 0.005 
Systolic BP, mm Hg 0.211 0.033 
Diastolic BP, mm Hg 0.212 0.033 
IL-4, pg/ml -0.078 0.438 
IL-6, pg/ml -0.177 0.075 
IL-8 pg/ml 0.082 0.415 
Glucose, mmol/L -0.232 0.019 
LDL, mmol/L 0.425 0.000008 
HDL, mmol/L -0.179 0.072 
Total cholesterol, mmol/L 0.109 0.281 
IgE, IU/mL 0.212 0.032 
Eosinophils, % -0.188 0.058 
 
According to the results of the assessment of the correlation of BMI and clinical and anamnestic 
data of overweight patients with BA, a positive relationship was found with the age of patients (ager=0.299, 
p=0.002), the number of points on the ACQ-5 questionnaire, which indicates the level of BA control (ACQ-
5r=0.274, p=0.005), as well as a negative correlation with the RF – FEV1 index (FEV1r=-0.206, p=0.038) 
(p<0.05). 
A probable positive correlation was noted between BMI and the blood pressure – systolic 
(SBPr=0.211, p=0.033) and diastolic (DBPr=0.212, p=0.033). 
According to the results of the assessment of the links between BMI and systemic inflammation 
indices (IL-4, IL-6, IL-8), no associations in the group of BA patients with overweight were found. Instead, 
there is a probable association between BMI and indices of the BA – positive allergic profile with IgE 
levels (IgEr=0.212, p=0.032) and the tendency of negative association with blood eosinophil levels 
(eosinophilsr=-0.188, p=0.058). 
An increase in body weight (in terms of BMI) has a likely correlation with metabolic changes in 
BA patients with overweight: a negative association with blood glucose levels and a positive association 
with LDL levels are likely (p<0.05). 
Thus, our data demonstrate the negative effect of excess body weight on the course of BA.  
In our study, increased BMI in asthma patients was likely to be associated with increasing patient's 
age, longer BA duration, and duration of ICS use, which may indicate a worsening of metabolic disorders 
with age and course of the disease. Instead, in a study by T. Villeneuve et al. it is indicated that the increase 
in the number of BA cases among obese patients does not depend on the age of the patient [10]. Current 
studies identify two main phenotypes by age of BA onset in combination with obesity – early-onset BA 
and late-onset BA [5], which differ significantly in gender composition, course, and pathogenetic 
mechanisms (primary obesity or BA) [7]. Therefore, depending on the predominance of one or another 
phenotype in the studied population, the association of age with the risk of developing BA with obesity 
will change. However, there is no doubt that the age of onset of BA comorbid with obesity is important to 
determine the leading phenotype of the disease, which in turn is important for predicting the course and 
effectiveness of basic treatment.  
Comparative analysis of groups of normal and overweight BA patients did not reveal significant 
differences in the levels of RF violation and control of symptoms by ACQ-5. However, the correlation 
analysis allowed us to investigate the probable negative impact of increased BMI in patients with asthma 
on RF and disease control, which indicates a more severe course of the disease on the background of 
overweight. These results are confirmed in studies by U. Peters et al. [9], A. Mohan et al. [8], O.A. Carpaij 
[2] and others [10, 11]. 
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The comorbid course of BA and obesity may contribute to the development of other comorbidities, 
such as cardiovascular disease, as evidenced by recent studies on this problem [2, 11]. Our study revealed 
an increase in the mean level of diastolic blood pressure in the group of patients with BA and overweight, 
as well as a probable positive correlation between BMI and levels of systolic and diastolic blood pressure, 
which may indicate an increased risk of hypertension and diastolic dysfunction in this group of patients. 
Another group of factors that contribute to the development of cardiovascular disease are disorders of 
carbohydrate and lipid metabolism, which are observed in patients with BA with overweight and are likely 
to be associated with increased BMI. 
The comparative study did not reveal a probable difference in the indicators of the allergic profile 
of BA depending on BMI, although a probable correlation was found between the level of IgE and BMI in 
the group of patients with asthma with elevated BMI. This result can be explained by a diverse group of 
patients by phenotypes, because the increase in IgE and eosinophils in the blood is more characteristic of 
the BA phenotype with obesity with early onset of the disease [9, 12]. 
All of the above indicates a significantly worse course of asthma in obesity, so understanding the 
relationship between these conditions can help in finding new therapeutic strategies for the treatment of 
this group of patients, which should include both pharmacological approach and specific treatment of 
obesity – a combination of diet and exercise. 
 
Conclusions 
1. Patients with asthma with overweight differ from patients with BA with normal body weight 
probably longer duration of asthma and the use of ICS by 28.6 % and 27.0 %, respectively, as well as 
higher by 5.3 % level of diastolic blood pressure (p<0.05). 
2. The presence of excess body weight in patients with BA compared with normal weight patients 
is associated with major metabolic disorders – a probable decrease in HDL (by 65.7 %), increase in LDL 
(by 13.2 %) and glucose levels (by 5.1 %), as well as an increase in systemic inflammation – IL-6 (by 
31.8 %) (p<0.05), which in turn indicates the presence of a higher cardiovascular risk in this group of 
patients. 
3. Overweight patients with BA have likely correlations of BMI with age, RF, symptom control 
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